Know Cancer

forgot password

An Open-Label Phase I Study of the Safety of and Efficacy of RAD001 in Combination With Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

Phase 1
18 Years
Not Enrolling
Multiple Myeloma

Thank you

Trial Information

An Open-Label Phase I Study of the Safety of and Efficacy of RAD001 in Combination With Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

- Researchers are looking for the highest doses of RAD001 and lenalidomide used in
combination that can be given safely so small groups of people will be enrolled in
steps in this trial. The first group will be given a certain dose of RAD001 and a
certain dose of lenalidomide. If they have few or manageable side effects, the next
small group of people will be enrolled with a higher dose of RAD001 and/or a higher
dose of lenalidomide. This will continue until the highest dose of the drugs used is

- Study treatment will be given in 28 day cycles. Both RAD001 and lenalidomide are pills
that are taken orally. Both drugs will be started on the same day. RAD001 will be
taken either every other day or every day for the first 3 weeks (days 1-21) of each
28-day cycle. Lenalidomide will be taken daily for the first 3 weeks (days 1-21) of
each cycle.

- Participants will come to the clinic weekly during the first cycle to monitor side
effects. The following will be performed at these clinic visits: physical examination,
medical history update, questionnaires, and blood work.

- On cycles 2-8, participants will come to the clinic on Day 1 of each cycle. The
following will be performed at this clinic visit: physical examination, medical history
update, questionnaire, and blood word.

- At the end of cycle 8, a skeletal survey, bone marrow aspiration and biopsy will be
performed to check response to study treatment.

- Participants may continue to receive RAD001 and lenalidomide beyond 8 cycles if their
cancer does not get worse and they do not have unacceptable side effects.

Inclusion Criteria:

- Subject was previously diagnosed with multiple myeloma bases on standard criteria
listed in protocol

- Patients must have relapsed or relapsed/refractory disease

- 18 years of age or older

- All necessary baseline studies for determining eligibility must be obtained within 21
days prior to enrollment

- ECOG Performance Status of 0 to 2

- Able to take aspirin (81 or 325mg) daily as prophylactic anticoagulation

- Prior thalidomide/lenalidomide therapy is allowed

- Able to take bactrim

- Female of childbearing potential must have a negative serum or urine pregnancy test

Exclusion Criteria:

- Renal insufficiency

- Concommitant therapy medications that include corticosteroids or other chemotherapy
that is or may be active against myeloma or therapy with chemotherapy within 2 weeks
prior to day 1. Nitrosoureas must be discontinued 6 weeks prior to day 1.
Concurrent radiation therapy is not permitted.

- Subjects with evidence of mucosal or internal bleeding and/or platelet refractory

- Subjects with poorly controlled diabetes mellitus

- Subjects with an ANC < 10-00 cells/mm3

- Subjects with a hemoglobin < 8.0 g/Dl

- AST (SGOT and ALT (SGPT) greater or equal to 2x ULN

- Prior therapy with RAD001

- Known hypersensitivity to thalidomide or lenalidomide

- Any condition, including laboratory abnormalities, that in the opinion of the
Investigator, places the subject at unacceptable risk if he/she were to participate
in the study

- Clinically relevant active infection or serious co-morbid medical conditions such as
recent thromboembolic disease are ineligible if occurred less than 2 weeks prior to
enrollment or clinically unstable

- Chronic obstructive or chronic restrictive pulmonary disease, difficult to control
diabetes, upper gastrointestinal ulceration, and cirrhosis

- Prior malignancy (within the last 3 years) except for adequately treated basal cell
or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ
prostate cancer or other cancer for which the subject has been disease-free for at
least 3 years

- Pregnant or breast-feeding females

- Prior treatment with any investigational drug within preceding 4 weeks

- Major surgery, and or radiation with 2 weeks of study initiation

- Uncontrolled leptomeningeal disease

- Prior treatment with other mTOR inhibitors

- The use of G-CSF is not permitted to render the patient eligible fot the study

- POEMS syndrome

- Known HIV infection

- Known active Hepatitis B or C infection

- Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV
heart failure, uncontrolled ventricular arrhythmias, or electrocardiographic evidence
of acute ischemia or active conduction system abnormalities

- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of RAD001

- Patients with active, bleeding diathesis or on oral anti-vitamin K medication

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the safety of RAD001 when given in combination with lenalidomide and to identify the maximum tolerated dose (MTD) as well as a recommended Phase 2 dose for the combination in this patient population.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Noopur Raje, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Massachusetts General Hospital


United States: Food and Drug Administration

Study ID:




Start Date:

June 2008

Completion Date:

November 2009

Related Keywords:

  • Multiple Myeloma
  • relapsed multiple myeloma
  • refractory multiple myeloma
  • RAD001
  • lenalidomide
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Mayo Clinic Rochester, Minnesota  55905
Memorial Sloan-Kettering Cancer Center New York, New York  10021
Medical College of Wisconsin Milwaukee, Wisconsin  53226
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Massachusetts General Hospital Boston, Massachusetts  02114-2617